June 15, 2023
AntlerA Norrin/Wnt-agonist antibody through a strategic partnership with EyeBio enters clinical trials for treatment of retinopathies.
AntlerA previously reported the development of a Norrin/Wnt-mimetic for treatment of leaky blood vessels in the eye.
“We are pleased to support EyeBio in the development and advancement of EYE103, a Norrin/Wnt-mimetic, into the clinic. Built based on AntlerA’s ANT-Pharm platform the tetravalent antibody molecule binds specifically to FZD4/LRP5 receptors leading to Wnt-signaling and restoration of blood vessels integrity in the eye.” said Dr. Sekar Seshagiri, CEO, AntlerA Therapeutics. He further added “This is a first-in class molecule for treatment of diabetic retinopathy and several pediatric retinal diseases such as FEVR/Norrie, Coats, and ROP”
About AntlerA Therapeutics, Inc.
AntlerA Therapeutics is a regenerative medicines company focused on developing novel protein therapeutics that function by modulating Wnt signaling to harness the regenerative potential of tissue resident stem cells.
For more information, please visit www.antlera.com
April 22, 2024
Novel Concepts Medical’s case study shows improvement in a colon cancer patient with metastases in his liver and shrinkage of his tumor size after usi...
April 16, 2024
It is with great pleasure that Sakura Finetek Europe announces the appointment of Jaap Stuut as the President and General Manager, effective today. Ja...
April 8, 2024
BBI Solutions OEM Limited (BBI), the premier independent manufacturer of immunodiagnostic reagents globally, has announced the successful closing of t...
Life Science Newswire is a division of BioStrata.
BioStrata Ltd., Endurance House, Vision Park, Histon, Cambridge, CB249ZR,
Company registration: 8233225